Navigation Links
Pharmos Corporation Reports 2011 Fourth Quarter and Full Year Results
Date:2/17/2012

that affects roughly 10-15% of U.S. adults, primarily women. Pharmos is seeking a partnership with another pharmaceutical company to further develop this promising compound for IBS as well as for Levotofisopam after the current gout trial. The Company also has a proprietary technology platform centering on discovery and development of synthetic cannabinoid compounds, with a focus on CB2 receptor-selective agonists. Various CB2-selective compounds from Pharmos's pipeline have been the subject of completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and other disorders.  These are available for licensing/partnering.

Safe Harbor StatementStatements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.  Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.PHARMOS CORPORATIONConsolidated Statements of Operations Three months endedTwelve months endedDecember 31,December 31,2011201020112010ExpensesResearch and development

$ 198,992

$ 117,771

$ 870,592

$ 497,935Grants

-

(244,479)

-

(244,479)Research and development, net

198,992

(126,708)

870,592

253,456General and administrative

207,184

251,593

1,005,548

1,187,335Depreciatio
'/>"/>

SOURCE Pharmos Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmos Corporation Reports 2011 Second Quarter Results
2. Pharmos Corporation Reports 2010 Third Quarter Results
3. Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
4. Pharmos Corporation Reports 2009 Third Quarter Results
5. Pharmos Issues Business Update on Dextofisopam Trial and Financing
6. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
7. Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
8. Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure
9. Unilife Corporation Announces Financial Results for Fiscal Year 2012 Second Quarter
10. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
11. Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , April 28, 2015  Illnesses know no work schedule ... places of business. If you,ve ever woken up the morning ... sick as the proverbial dog, or if you,ve been putting ... how to fit it into your schedule, you,ve experienced this ... House Call Doctor Los Angeles offers an alternative for busy ...
(Date:4/28/2015)... 28, 2015 UPM Pharmaceuticals, an independent drug ... prestigious "2015 Industry Choice Award" in the Mid-sized and ... Life Science Leader magazine during the annual CMO ... York City on March 18, 2015. The ... service organizations based on survey responses from thousands of ...
(Date:4/28/2015)... 28, 2015  The Physician-Patient Alliance for Health ... , RRT has joined the Physician-Patient Alliance Board ... well-respected Registered Respiratory Therapist who has practiced in the ... for his excellent work on critical patient safety issues. ... Care (AARC) at various conferences addressing the need ...
Breaking Medicine Technology:Your Health and Your Schedule Should not be at War 2UPM Pharmaceuticals Awarded The 2015 Industry Choice Award for Mid-sized and Emerging Pharma 2Noted Respiratory Therapist and AARC Representative Gene Gantt Joins Physician-Patient Alliance for Health & Safety Advisory Board 2
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... by Blair A. Jobe, MD, FACS , has ... replacing esophageal tissue with extracellular matrix (ECM) can help ... lethal form of esophageal cancer. , ECM is a ... for cell attachment and migration and signals that guide ...
(Date:4/28/2015)... 2015 As the Muscular Dystrophy ... services programs, the organization has hired Scientific Program ... MDA from Fidelity Biosciences Research Initiative where, as ... in neurodegenerative diseases such as Alzheimer’s Disease, and ... time at Fidelity, she was a junior faculty ...
(Date:4/28/2015)... 2015 Researchers from four US medical ... a steroid prior to pemetrexed (Alimta) chemotherapy may keep ... Click here to read the full story on ... Raabe College of Pharmacy in Ohio, Stanford Cancer Institute ... Healthcare in Kentucky gave a single dose of dexamethasone ...
(Date:4/28/2015)... 2015 SeniorCare.com has published the ... reality problem Americans have regarding aging and long-term care ... care services as they age, 63% of Americans do ... In the report, Carol Marak of SeniorCare.com interviewed 44 ... Health Care Association and The Scan Foundation. The experts ...
(Date:4/28/2015)... Enrollment in programs designed to coordinate ... in April, according to the editors of Atlantic ... Eligibles Database , an online subscription resource that ... community. This is a 14% increase since the ... January, but only covers about a quarter of ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Enrollment in Duals Programs Increases 14%, New AIS Database Finds 2
... complicated. Thomas Jefferson University biochemistry researchers have shown ... insect molting hormone doesn,t activate and repress genes as once ... out-competed by a heme-binding receptor to repress the same genes ... For the last 20 years, the nuclear receptor known ...
... U.S. Food and Drug Administration and the National Institutes ... of tobacco users to monitor and assess the behavioral ... The initiative, called the Tobacco Control Act National Longitudinal ... collaboration on tobacco regulatory research since Congress granted FDA ...
... and diagnosis of open angle glaucoma important so that treatment ... developing to prevent or avoid further vision loss. Writing in ... Engineering and Informatics , researchers in the US have analyzed ... so that patients can be screened at an earlier stage ...
... , THURSDAY, Oct. 6 (HealthDay News) -- ,Anemia ... have different types of surgery, not just heart operations, a ... anemia have worse outcomes after heart surgery, but anemia,s impact ... deficient in red blood cells. For the new ...
... had been given DES, the first synthetic form of estrogen, ... in the womb (in utero) is associated with many reproductive ... conditions. The results of this analysis, conducted by researchers at ... of Health, and collaborators across the country, were published Oct. ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. ... forms of multiple sclerosis appears to reduce relapse rates and ... 3 trial. The experimental drug, teriflunomide, is one of ... and may, if approved, be a good choice for many ...
Cached Medicine News:Health News:Nuclear receptors battle it out during metamorphosis in new fruit fly model 2Health News:FDA and NIH announce joint study on tobacco use and risk perceptions 2Health News:Detecting glaucoma before it blinds 2Health News:Anemia Could Add to Surgical Risks 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 3Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3
... Introducing the new large ... new handpieces function as both ... the ultimate in flexibility. Its ... always wanted with the security ...
... 7600 Oscillating Saw offers unparalleled ... thanks to its 14.4V NiMH ... head may be rotated into ... any plane and will accept ...
... Breakthrough in Battery Powered Orthopedic Systems., ... new addition to the Hall® Surgical line ... System is the first and only software ... market. It is a full-function orthopedic power ...
... Introducing the new large ... Our new handpieces function ... electric instruments, offering the ... the versatility the industry ...
Medicine Products: